Genomic data with clinical outcome data from routine practice data from Dana-Farber Cancer Institute, Boston, MA, USA
To answer questions about new cancer therapies, including: what diseases should they be used for? What doses of new drugs are most effective? And which patients can benefit the most from them?
- Study design
- Patients' cohort
- Sources of Recruitment
Number of participants
- Number of participants
- Number of participants with biosamples
Availability of data and biosamples
No coverage data about the variables classifications are available.